Food for Thought...: Toxicity testing in the 21st century beyond environmental chemicals

Altex

Volumn 32, Issue 3, 2015, Pages 171-181

  Rovida, Costanza ^a   Asakura, Shoji ^b   Daneshian, Mardas ^a   Hofman Huether, Hana ^c   Leist, Marcel ^a   Meunier, Leo ^d   Reif, David ^e   Rossi, Anna ^f   Schmutz, Markus ^g   Valentin, Jean Pierre ^h   Zurlo, Joanne ⁱ   Hartung, Thomas ^a,i  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b EISAI CO LTD   (Japan)

^c Eurofins Medinet Inc   (Germany)

^d Danone Food Safety Center   (Netherlands)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^g BERATA AG   (Switzerland)

^h UCB PHARMA   (Belgium)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Drugs; Food ingredients; Safety assessment; Tox21c

Indexed keywords

ENVIRONMENTAL CHEMICAL;

ARTICLE; DRUG INDUSTRY; FOOD; FOOD INDUSTRY; FOOD SAFETY; HUMAN; NONHUMAN; RISK ASSESSMENT; TOXICITY TESTING; ANIMAL; ANIMAL TESTING ALTERNATIVE; DRUG APPROVAL; DRUG SCREENING; GOVERNMENT; IN VITRO STUDY; PROCEDURES; SAFETY; STANDARDS; UNITED STATES;

ANIMAL TESTING ALTERNATIVES; ANIMALS; DRUG APPROVAL; DRUG EVALUATION; DRUG INDUSTRY; HUMANS; IN VITRO TECHNIQUES; RISK ASSESSMENT; SAFETY; TOXICITY TESTS; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

EID: 84938603406     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.1506201     Document Type: Article

References (54)

1. Alépé e, N., Bahinski, T., Daneshian, M. et al. (2014). State-of-the-Art of 3D cultures (organs-on-A-chip) in safety testing and pathophysiology-A t4 report. ALTEX 4, 441-477. http://dx.doi.org/10.14573/altex1406111
2. Andersen, M., Betts, K., Dragan, Y. et al. (2014). Developing microphysiological systems for use as regulatory tools-challenges and opportunities. ALTEX 31, 364-367. http://dx.doi.org/10.14573/altex.1405151
3. Arrowsmith, J. (2011). Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 10, 328-329. http://dx.doi.org/10.1038/nrd3439
4. Arrowsmith, J. and Miller, P. (2013). Trial Watch: Phase II and Phase III attrition rates 2011-2012. Nat Rev Drug Disc 12, 569. http://dx.doi.org/10.1038/nrd4090
5. Bass, A. S., Cartwright, M. E., Mahon, C. et al. (2009). Exploratory drug safety: a discovery strategy to reduce attrition in development. J Pharmacol Toxicol Methods 60, 69-78. http://dx.doi.org/10.1016/j.vascn.2009.04.194
6. Bouhifd, M., Hartung, T., Hogberg, H. T. et al. (2013). Review: Toxicometabolomics. J Appl Toxicol 33, 1365-1383. http://dx.doi.org/10.1002/jat.2874
7. Bouhifd, M., Hogberg, H. T., Kleensang, A. et al. (20 14). Mapping the human toxome by systems toxicology. Basic Clin Pharmacol Toxicol 115, 24-31. http://dx.doi.org/10.1111/bcpt.12198
8. Cases, M., Briggs, K., Steger-Hartmann, T. et al. (2014). The eTO X data-sharing project to advance in silico drug-induced toxicity prediction. Int J Mol Sci 15, 2136-2154. http://dx.doi.org/10.3390/ijms151121136
9. Chapman, K., Creton, S., Kupferschmidt, H. et al. (2010). The value of acute toxicity studies to support the clinical management of overdose and poisoning: A cross-discipline consensus. Regul Toxicol Pharm 58, 354-359. http://dx.doi.org/10.1016/j.yrtph.2010.07.003
10. Chapman , K. L., Holzgrefe, H., Black, L. et al. (2013). Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation. Regul Toxicol Pharm 66, 88-103. http://dx.doi.org/10.1016/j.yrtp h.2013.03.001
11. Coecke, S., Balls, M., Bowe, G. et al. (2005). Guidance on good cell culture practice. Altern Lab Anim 33, 261-287.
12. Cook, D., Brown, D., Alexander, R. et al. (20 14). Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nat Rev Drug Discov 13, 419-431. http://dx.doi.org/10.1038/nrd4309
13. EFSA 2009 Opinion of the scientific commi ttee on a request from efsa on existing approaches incorporating replacement, reduction and refinement of animal testing: Applicability in food and feed risk assessment EFSA J 1052 1-77 http://dx.doi.org/10.2903/j.efsa.2009.1052
14. EFSA (2011). Scientific opinion. Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment (69 pp.). EFSA J 9, 2379. http://dx.doi.org/10.2903/j.efsa.2011.2379.
15. EFSA (2012). Scientific opinion. Guidance for submission for food additive evaluations (60 pp.). EFSA J 10, 2760. http://dx.doi.org/10.2903/j.efsa.2012.2760.
16. EFSA (2014). Scientific report of EFSA. Modern methodologies and tools for human hazard assessment of chemicals (87 pp.). EFSA J 12, 3638. http://dx.doi.org/10.2903/j.efsa.2014.3638
17. EMA (2011). Statement of the EMA position on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of human and veterinary medicinal products. EMA/470807/2011.
18. EMA (2014). Concept paper on review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products. EMA/CHMP/CVMP/JEG-3Rs/704685/2012 (draft).
19. FDA (2013). Good Review Practice: Clinical Review of Investigational New Drug Applications. http://www.fda.gov/down loads/Drugs/GuidanceComplianceRegulatoryInformation/UCM377108.pdf
20. Evans, E. W. (2014). Regulatory forum commentary: Is unexpected immunostimulation manageable in pharmaceutical development? Toxicol Pathol 42, 1053-1057. http://dx.doi.org/10.1177/0192623313513075
21. Ewart, L., Aylott, M., Deurinck, M. et al. (2014). The concordance between nonclinical and Phase I clinical cardiovascular assessment from a cross-company data sharing initiativ e. Toxicol Sci 142, 427-435. http://dx.doi.org/10.1093/toxsci/kfu198
22. Hay, M., Thomas, D. W., Craighead, J. L. et al. (2014). Clinical development success rates for investigational drugs. Nat Biotech 32, 40-51. http://dx.doi.org/10.1038/nbt.2786
23. Hartung, T. (2007). Food for thought ⋯ on cell culture. ALTEX 24, 143-152. http://www.altex.ch/resources/altex-2007-3-143-147-FFT-HartungE.PDF
24. Hartung, T. and Zurlo, J. (2012). Food for thought ⋯ Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 29, 251-260. http://www.altex.ch/Current-issue.50.htmliid=133&aid=1
25. Hartung, T. (2013). Look Back in anger-what clinical studies tell us about preclinical work. ALTEX 30, 275-291. http://www.altex.ch/All-issues/Issue.50.htmliid=142&aid=1
26. Har tung, T., Luechtefeld, T., Maertens, A. and Kleensang, A. (2013). Food for thought ⋯ Integrated testing strategies for safety assessment. ALTEX 30, 3-18. http://altweb.jhsph.edu/altex/30-1/FFTHartung.pdf
27. Hartung, T. (2014). 3D-A new dimension of in vitro research. Adv Drug Deliv Rev 70, 69-69. http://dx.doi.org/10.1016/j.addr.2014.04.003
28. Hornberg, J. J., Laursen, M., Brenden, N. et al. (2014). Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. Drug Discov Today 19, 1131-1136. http://dx.doi.org/10.1016/j.drudi s.2013.12.008
29. Horner, S., Robinson, S., Lees, D. et al. (2014). Target organ profiles in toxicity studies supporting human dosing: An assessment of recovery and chronic dosing. Regul Toxicol Pharmacol 70, 2 70-285. http://dx.doi.org/10.1016/j.yrtph.2014.07.008.
30. Huang, R., Sakamuru, S., Martin, M. T. et al. (2014). Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signa ling pathway. Sci Rep 4, 5664-5664. http://dx.doi.org/10.1038/srep05664
31. Igarashi, T., Nakane, S. and Kitagawa, T. (1995). Predictability of clinical adverse reactions of drugs by general pharmacology studies. J Toxicol Sci 20, 77-92. http://dx.doi.org/10.2131/jts.20.77
32. Kavlock, R., Chandler, K., Houck, K. et al. (2012). Update on EPA's ToxCast program: Providing high throughput decision support tools for chemical risk management. Chem Res Toxicol 25, 1287-1302. http://dx.doi.org/10.1021/tx3000939
33. Keating, C., Ewart, L., Grundy, L. et al. (2014). Translational potential of a mouse in vitro bioassay in pr edicting gastrointestinal adverse drug reactions in Phase I clinical trials. Neurogastroenterol Motil 26, 980-989. http://dx.doi.org/10.1111/nmo.12349
34. Kleensang A.,Maertens A.,Rosenberg M.,et al. 2014 t4 workshop report: Pathways of toxicity ALTEX 31 53-61 http://dx.doi.org/10.14573/altex.1309261
35. Kola, I., and Landis, J. (2004). Opinion: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711-716. http://dx.doi.org/10.1038/nrd1470
36. Krewski, D., Westphal, M., Andersen, M. E. et al. (2014). A framework for the next generation of risk science. Environ Health Perspect 122, 796-805. http://dx.doi.org/10.1289/ehp.1307260
37. Leist, M, Hasiwa, N., Rovida, C. et al. (2014). Consensus report on the future of animal-free systemic toxicity testing. ALTEX 31, 341-3 56. http://dx.doi.org/10.14573/altex.1406091
38. Lesko, L. J., Salerno, R. A., Spear, B. B. et al. (2003). Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: Report of the first FDA-PWG-PhRMA-DruSafe workshop. J Clin Pharmacol 43, 342-358. http://dx.doi.org/10.1177/0091270003252244
39. Manolis, E., Vamvakas, S. and Isaac M. (2011). New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics Clin Appl 5, 248-255. http://dx.doi.org/10.1002/prca.201000130
40. Marx, U., Walles, H., Hoffmann, S. et al. (2012). " Human-on-A-chip" developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man Altern Lab Anim 40, 235-257.
41. McKim, J. M. (2010). Building a tiered approach to in vitro predictive toxicity screening: A focus on assays with in vivo relevance. Comb Chem High Throughput Screen 13, 188-206. http://dx.doi.org/10.2174/138620710790596736
42. Neltner, T. G., Alger, H. M., Leonard, J. E. and Maffini, M. V. (2013). Data gaps in toxicity testing of chemicals allowed in food in the United States. Reprod Toxicol 42, 85-94. http://dx.doi.org/10.1016/j.reprotox.2013.07.023
43. NRC-National Research Council, Co mmittee on Toxicity Testing and Assessment of Environmental Agents (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC, USA: The National Academies Press.
44. Olson, H., Betton, G., R obinson, D. et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32, 56-67. http://dx.doi.org/10.1006/rtph.2000.1399
45. Ramirez, T., Daneshian, M ., Kamp, H. et al. (2013). Metabolomics in toxicology and preclinical research. ALTEX 30, 209-225. http://dx.doi.org/10.14573/altex.2013.2.209
46. Reif, D. M., Martin, M. T., Tan, S. W. et al. (201 0). Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environ Health Persp 118, 1714-1720. http://dx.doi.org/10.1289/ehp.1002180
47. Rovida, C., Alepee, N., Api, A. M. e t al. (2015). t4 workshop report: Integrated Testing Strategies (ITS) for safety assessment. ALTEX 32, 25-40. http://www.altex.ch/resources/altex-2015-1-025-040-Rovida-sva1.pdf
48. Sager, P. T., Gintant, G., T urner, J. R. et al. (2014). Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. Am Heart J 167, 292-300. http://dx.doi.org/10.1016/j.ahj.2013.11.004
49. Stallman Brown, E., Jacobs, A. and Fitzpatrick, S. (2012). Reproductive and developmental toxicity testing: from in vivo to in vitro. ALTEX 29, 333-339. http://www.altex.ch/resources/altex-2012-3-333-339-ConfRep.pdf
50. Truong, L., Reif, D. M., Mary, L. S. et al. (2014). Multidimensional in vivo hazard assessment using zebrafish. Toxicol Sci 137, 212-233. http://dx.doi.org/10.1093/toxsci/kft235
51. Valent in, J. P., Koerner, J., Willard, J. et al. (2013). Predictivity of non-clinical repolarization assay data for clinical TQT data in FDA database. Toxicol Lett 221, Suppl., S232-S233. http://dx.doi.org/10.1016/j.toxlet.2013.05.5 66
52. van der Laan, J. W., Chapin, R. E., Haenen, B. et al. (2012). Testing strategies for embryo-fetal toxicity of human pharmaceuticals. Animal models vs. in vitro approaches. Regul Toxicol Pharmacol 63, 115-123. http://dx.doi.org/10.1016/j.yrtph.2012.03.009
53. van der Meulen, B. M. J. (2013). The Structure of European Food Law. Laws 2, 69-98. http://dx.doi.org/10.3390/laws2020069
54. van Vliet, E., Danesian, M., Beilmann, M. et al. (2014). Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 31, 479-493. http://dx.doi.org/10.14573/altex.1405271